Department of Nuclear Medicine, University Hospital RWTH Aachen, 52074 Aachen, Germany.
Department of Radiology and Nuclear Medicine, Maastricht University Medical Center, 6229HX Maastricht, The Netherlands.
Nutrients. 2021 Mar 19;13(3):994. doi: 10.3390/nu13030994.
INTRICATE is a prospective double-blind placebo-controlled feasibility study, assessing the influence of combined vitamin K2 and vitamin D3 supplementation on micro-calcification in carotid artery disease as imaged by hybrid Sodium [F]Fluoride (Na[F]F) positron emission tomography (PET)/ magnetic resonance imaging (MRI). Arterial calcification is an actively regulated process and results from the imbalance between calcification promoting and inhibiting factors. Considering the recent advancements in medical imaging, ultrasound (US), PET/MRI, and computed tomography (CT) can be used for the selection and stratification of patients with atherosclerosis. Fifty-two subjects with asymptomatic carotid artery disease on at least one side of the neck will be included in the study. At baseline, an Na[F]F PET/MRI and CT examination will be performed. Afterwards, subjects will be randomized (1:1) to a vitamin K (400 µg MK-7/day) and vitamin D3 (80 µg/day) or to placebo. At the 3-month follow-up, subjects will undergo a second Na[F]F PET/MRI and CT scan. The primary endpoint is the change in Na[F]F PET/MRI (baseline vs. after 3 months) in the treatment group as compared to the placebo arm. Secondary endpoints are changes in plaque composition and in blood-biomarkers. The INTRICATE trial bears the potential to open novel avenues for future large scale randomized controlled trials to intervene in the plaque development and micro-calcification progression.
INTRICATE 是一项前瞻性、双盲、安慰剂对照的可行性研究,旨在评估联合维生素 K2 和维生素 D3 补充对颈动脉疾病中混合 [F]氟酸钠(Na[F]F)正电子发射断层扫描(PET)/磁共振成像(MRI)成像的微钙化的影响。动脉钙化是一个活跃调节的过程,是由钙化促进和抑制因素之间的失衡引起的。考虑到医学成像的最新进展,超声(US)、PET/MRI 和计算机断层扫描(CT)可用于选择和分层动脉粥样硬化患者。52 名颈侧至少有一侧无症状颈动脉疾病的受试者将纳入该研究。在基线时,将进行 Na[F]F PET/MRI 和 CT 检查。之后,受试者将按 1:1 随机分配至维生素 K(400 µg MK-7/天)和维生素 D3(80 µg/天)或安慰剂组。在 3 个月的随访时,受试者将再次进行 Na[F]F PET/MRI 和 CT 扫描。主要终点是与安慰剂组相比,治疗组中 Na[F]F PET/MRI(基线与 3 个月后)的变化。次要终点是斑块成分和血液生物标志物的变化。INTRICATE 试验有可能为未来的大规模随机对照试验开辟新的途径,以干预斑块的发展和微钙化的进展。